Haemophilia (2015), 21 (Suppl. 2), 1–2
PROGRAMME WEDNESDAY 11.2.2015 10.00-12.00
Multidisciplinary educational session Key aspects and challenges in a patient journey from different perspectives: Doctors, Nurses, Physiotherapists – Elsbeth Mueller-Kaegi, Switzerland, Robert Klamroth, Germany, Klaus Österholm, Finland and Gerry Dolan, United Kingdom
12.00-13.00
Lunch and The Multidisciplinary meeting with lunch
13.00-14.30
Presidential session 1 Welcome – Philippe de Moerloose and Riitta Lassila Coagulation history in Finland – Otto Lindberg, Finland Update of EUHANET – Mike Makris, United Kingdom Interaction between clinics and laboratory in inherited bleeding disorders – Clinical issues – Alberto Tosetto, Italy Laboratory issues – Ian Jennings, UK
14.30-15.00
Coffee break – posters
15.00-16.30
Session 2: Carriers and neonates Chairs: Elena Santagostino and Kathelijn Fischer From the defective gene to the bleeding patient – Roseline d’Oiron, France Management of pregnant women with congenital bleeding disorders – Sue Pavord, UK Newborn with haemophilia – State of the Art management – Herve Chambost, France
16.30-18.00
Industrial symposia
18.30-20.00
Industrial symposia
THURSDAY 12.2.2015 8.30-10.00
Session 3: Primary haemostasis Chairs: Angiola Rocino and Gerry Dolan Von Willebrand disease: under- and over-diagnosis and management – Jeroen Eikenboom, Netherlands Inherited platelet disorders – Christel Van Geet, Belgium Platelet procoagulant activity – Riitta Lassila, Finland
10.00-10.30 10.30-12.00
Coffee break – posters Session 4: Emerging therapies of bleeding disorders Chairs: Mike Makris and Elina Armstrong How to treat severe haemophilia without FVIII? – Midori Shima, Japan Emerging therapies for rare bleeding disorders: FV, FX – Flora Peyvandi, Italy How should we use long-acting FVIII / FIX? – Erik Berntorp, Sweden
© 2015 The Authors Haemophilia © 2015 John Wiley & Sons Ltd
1
2
PROGRAMME
12.00-13.00
Lunch – poster session I
13.00-14.30
Session 5: Interaction between laboratory and clinics Chairs: Pål Andre Holme and Robert Klamroth Challenges of FVIII and FIX assays and interpretation – Christopher Hughes, UK Do global assays have a role in clinical practice? – Pa˚l Andre Holme, Norway Acquired bleeding disorders associated with direct oral anticoagulants – Sophie Susen, France
14.30-15.00
Coffee break – posters
15.00-16.30
Industrial symposia
16.45-18.00
General assembly
19.30-21.30
City Hall Helsinki – gathering for all participants (pre-signing up needed)
FRIDAY 13.2.2015 8.30-10.00
Industrial symposia
10.00-10.30
Coffee break – posters
10.30-12.00
Session 6: Cost of care Chairs Cedric Hermans and Riitta Lassila Population pharmacokinetics for busy clinicians and active patients: how to get the most out of it? – Alfonso Lorio, Canada How should cost effectiveness be analyzed in daily practice? – Katarina Steen-Carlsson, Sweden Tender and procurements for factor concentrates in Europe – Brian O’Mahony, EHC, Ireland Can we afford ITI in adults? Why and how? – Aino Lepäntalo, Finland
12.00-13.00
Lunch – poster session II
13.00-14.00
Late-breaking sessions Chairs: Philippe de Moerloose and Jan Astermark Poster awards Inhibitor development according to FVIII concentrate in PUPs: how to interpret current evidence? – Marijke Van den Berg, The Netherlands and Alfonso Iorio, Canada Discussion
Adjourn
Haemophilia (2015), 21 (Suppl. 2), 1–2
© 2015 The Authors Haemophilia © 2015 John Wiley & Sons Ltd
Copyright of Haemophilia is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.